SciELO - Scientific Electronic Library Online

 
vol.34 número2Trombosis venosa cerebral índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Archivos de Medicina Interna

versión impresa ISSN 0250-3816versión On-line ISSN 1688-423X

Resumen

PINEIRO, Dra. Natalia; CORREA, Fernando  y  RAMAGLI, Alicia. Treating Rheumatoid Arthritis with Anti-TNF. : Experience in Uruguay. Arch. Med Int [online]. 2012, vol.34, n.2, pp.38-42. ISSN 0250-3816.

Abstract: Arch Med Interna 2012 - 34(2): 38-41 Rheumatoid Arthritis (RA) is a systemic autoimmune disease, associated to an impairment of quality of life and increased morbimortality. Remissive therapies of RA include therapies with Disease Modifying Anti Rheumatic Drugs (DMARDs) and Biologic Agents. Therapy with the Anti-Tumor Necrosis Factor (Anti-TNF) was incorporated to the drugs reimbursed by the National Resource Fund (FNR) in March 2010. The study assessed a cohort of patients that started therapy before May 1 2011. Objectives: to characterize the population and to evaluate the efficacy outcomes of therapy, based on the evolution of DAS 28 scores. Results: 69 patients were enrolled. The mean pre and post therapy DAS 28 scores showed improvement (p < 0.05). Improvement criteria in 76.4% (low grade activity 37.3% and remission 14.9%). Adverse effects in 20 patients (in 3 cases it led to discontinuation of therapy). Drug changes, primary cause: treatment failure (8/9). Conclusions: Over 70% achieve improvement criteria; hence, although the results in this first evaluation of the response may be classified as good, they need to be monitored with time.

Palabras clave : Keywords: Rheumatoid arthritis, AntiTNF, DAS28, Adalimumab, Etanercept, Infliximab..

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons